A second punch against hepatitis b: interferon after RNA drugs may clear the virus

NCT ID NCT06923280

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial tests whether giving pegylated interferon to people with chronic hepatitis B—after they have already received an antisense oligonucleotide or small interfering RNA treatment—can clear the hepatitis B surface antigen from their blood. About 72 adults who saw a significant drop in that antigen during prior therapy will be randomly assigned to start interferon right away or wait 24 weeks. The goal is to see if this sequential approach leads to a functional cure, where the virus stays undetectable even after treatment stops.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pegylated interferon-alpha
What this could lead to
If successful, this approach could help more people with chronic hepatitis B achieve a functional cure—clearing the virus from their blood without lifelong medication.
What could go wrong
This is an early-stage trial with only 72 participants, and interferon therapy can cause flu-like symptoms, fatigue, and mood changes. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Ditan Hospital

    RECRUITING

    Beijing, China, China

  • Huashan Hospita

    RECRUITING

    Shanghai, China, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.